Please click on an icon below to view our free company specific research and monthly newsletter. You must be a registered user on our website to access the research and newsletter.
Please visit our industry pages, where we provide investment considerations, daily stories, videos & more for the 12 industries listed below:
A Vista Partners’ Commentary “Soligenix (SNGX)’s Combination of RiVax™ & VeloThrax™ Induces Protective Immunity to Both Ricin Toxin & Anthrax Toxin Exposure”July 9, 2014 by jheerdink
Soligenix, Inc. (SNGX) is a Princeton, NJ based clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. Soligenix is developing proprietary formulations of oral BDP (beclomethasone 17,21-dipropionate) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn’s disease (SGX203), acute radiation enteritis (SGX201) and chronic Graft-versus-Host disease (orBec®), as well as developing its novel innate defense regulator (IDR) technology SGX942 for the treatment of oral mucositis. — Read more
Who We Are
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm’s professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista’s mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes. CLICK HERE to view past performance.